fibrillation and a defined CHA 2 DS 2 -VASc score of 2 or greater, unless contraindicated, receive long-term anticoagulation therapy. 6 The guidelines do not address anticoagulation issues specific to patients with chronic liver disease. Nevertheless, a recent observational study found a lower risk of ischemic stroke and a positive net clinical benefit with warfarin compared with non-treatment in this patient population. 7 Warfarin has been the only drug approved for the prevention of stroke in patients with atrial fibrillation until the recent Food and Drug Administration's (FDA) approvals of five novel direct oral anticoagulant (DOAC) agents indicated in patients with non-valvular atrial fibrillation. The DOACs differ from vitamin K antagonists (VKAs) in their action mechanism because of direct inhibition of proteins of the coagulation cascade. They have more predictable pharmacokinetics leading to fixed and convenient dosing regimens, no need for routine monitoring, less drug-drug interactions, as well as a rapid onset and offset of action. Additionally, many DOAC agents demonstrated greater stroke and systemic embolism protection 8, 9 as well as lower major bleeding, 9 ,10 intracranial hemorrhage rates, 9, 11 and hemorrhagic stroke 8 rates compared to warfarin in atrial fibrillation.
Cirrhotic patients, however, have been excluded from DOAC clinical trials [8] [9] [10] [11] leading to limited recommendations on the use of these agents in patients with liver dysfunction based on pharmacokinetic data. More recent retrospective studies [12] [13] [14] have demonstrated safe use of DOAC agents in patients with compensated cirrhosis, leading some clinicians to use these agents with caution in selected patients with chronic liver disease. However, given the small sample sizes of these studies, more data are needed to establish the safety of various DOAC agents in chronic liver disease population. In this study, we tested the hypothesis that the use of DOAC agents in patients with chronic liver disease and atrial fibrillation poses a higher bleeding risk compared to warfarin.
| ME THODS

| Study design, site, and subjects
This was a retrospective cohort study of adult patients with chronic liver disease at an urban academic health system, who were initiated on oral anticoagulants from May 1, 2009 to May 1, 2016 for stroke prevention in atrial fibrillation. Patients were excluded from the study if the investigators were unable to ascertain the use of an anticoagulant within a year of the index date due to missing documentation. For the sample size calculation, we assumed a 15% yearly rate of all-cause hemorrhage in warfarin patients and the ability to include at least 70 DOAC patients. We estimated the need to include at least 70 warfarin patients (1:1 warfarin to DOAC ratio) to detect a large effect size (Cox hazard ratio of 2.0) with 80% power or at least 140 warfarin patients (2:1 warfarin to DOAC ratio) for >90% power.
As such, we sought to include all DOAC patients who fulfilled the inclusion criteria and matched them with randomly selected warfarin patients in a 2:1 ratio for a larger study power. 
| Definitions of exposure and outcome
The first documented prescription encounter for warfarin or a DOAC agent in a patient with documentation of atrial fibrillation and chronic liver disease diagnosis (ICD-9 codes 571.1 -571.9)
was treated as an index event. Following the index event, all emergency department visit or hospital admission data for bleeding events (Appendix S1 for ICD-9 codes) were extracted from a replicate of the electronic medical record system using healthcare 
| Statistical analysis
For the primary endpoint, the rate of all-cause bleeding was compared between patients on warfarin and patients on DOAC agents using a Kaplan-Meier estimator with a logrank test. In order to control for effects of confounding on the primary endpoint, we created by including many confounding variables in the model, 19 we performed a sensitivity analysis adjusting the primary endpoint for only the two strongest confounders (previous bleed and NSAID use) to create a model with a higher EPV.
For the secondary endpoint, the rate of major bleeding was compared between warfarin and DOAC patients. Additionally, the rate of all-cause bleeding was further stratified between individual DOAC agents. All analyses were performed using R version 3.3.3
(R Foundation for Statistical Computing; Vienna, Austria).
| RE SULTS
Eighty-nine DOAC patients and 180 warfarin patients were screened for inclusion in the study, of which 15 (17%) DOAC and 22 (12%)
warfarin patients were excluded due to missing documentation. In total, 75 DOAC and 158 warfarin patients were included in the final analysis. Of the DOAC patients, 11 (15%) were on apixaban, 35 (47%)
were on dabigatran, and 29 (39%) were on rivaroxaban. At baseline, the groups were similar in regard to clinical and demographic characteristics with the exception of concomitant use of NSAIDs and ChildTurcotte-Pugh Score (Table 1) .
Thirty-five patients experienced a bleeding event during the study period, 10 in the DOAC group and 25 in the warfarin group.
The most common bleeding events were gastrointestinal bleeding episodes (n = 27, 77%) [ Table 2 ] and epistaxis (n = 4, 11%). Other sites included bleeding from an epigastric wound (n = 1, 3%), joints (n = 1, 3%), retroperitoneum (n = 1, 3%), and central nervous system (n = 1, 3%).
For the primary endpoint, the all-cause bleeding rates were similar between DOAC and warfarin patients, at 8.4% per year in the DOAC group and 8.8% per year in the warfarin group (HR 0.9, 95% CI 0.4-1.8 for DOAC patients) ( Figure 1 ). This association did not significantly change when adjusted for demographic characteristics of patients and concomitant risk factors for bleeding (HR 1.0, 95% CI 0.4-2.3) ( Table 3) . The sensitivity analysis which employed a model with higher EPV ratio also did not demonstrate significant differences in the estimates for all-cause bleeding (HR 1.0, 95% CI 0.5-2.1).
For the secondary endpoints, the rate of major bleeding was similar between groups, at 3.3% per year in DOAC group and 3.9% individual DOAC agents were 6.5% (1 event) for apixaban, 9.2% (6 events) for dabigatran, and 7.7% (3 events) for rivaroxaban (P = .92).
The all-cause mortality rate was 8.1% per year in the warfarin and 8.3% per year in the DOAC group.
In the multivariable model that included choice of anticoagulant agent, demographic characteristics, and potential risk factors for bleeding (Table 3) , increased risk of all-cause bleeding was associ- 
| D ISCUSS I ON
Patients with chronic liver disease were excluded from trials of DOAC agents, leading to a lack of safety data on their use in this patient population requiring anticoagulation. 20 The and major bleeding (5% DOAC vs 11% traditional agents). Hum et al conducted a similar study in 45 patients, finding a non-significant decrease in the risk of all-cause bleeding in the DOAC arm (30% vs 56%) and an increased risk of major bleeding in traditional agent arm (28% vs 4%). However, there was a significantly higher exposure to anticoagulation in the group containing warfarin and enoxaparin (574 vs 319 days), which may account for the difference in bleeding rates that the investigators analyzed without regard to time on therapy, requiring further studies to confirm these findings.
Our study did not demonstrate significant differences in allcause bleeding or major bleeding between warfarin and DOACtreated patients with chronic liver disease, adding to the current body evidence from real-world clinical practice supporting the use of DOAC agents in compensated cirrhotic patients. It is important to note that our study population differed from those in previous studies in regard to the indication for anticoagulation (only atrial fibrillation), age (our patients were older at baseline), and the definition of traditional anticoagulation arm (we did not include low molecular weight heparins). While the previous studies did not include any patients on dabigatran, 47% of patients in the DOAC arm of our study were on dabigatran. Despite these differences, our study findings further support the evidence of similar rates of bleeding between DOAC and traditional agents. To our knowledge, this is the largest study to date evaluating the use of oral anticoagulants in this patient population.
The all-cause bleeding rates in our study patients were lower than previously reported on these agents, which may be due to a couple of factors. First, our definition of all-cause bleeding only included bleeding events that resulted in admission or emergency department visit, potentially missing less serious events that did not require an encounter with our health system. Additionally, we were only able to obtain bleeding encounters within our health system, allowing for potentially missed encounters at other health systems.
While these factors within our study design may have affected overall bleeding rates, they were unlikely to bias the hazard ratios, as the use of external health systems would not be related to choice of anticoagulant therapy. Finally, in our study, we reported bleeding rates in person-years to account for variation in follow-up length between groups, which could yield lower rates compared to counting overall bleeding events.
This study is subject to limitations. The patient population in this study may not reflect patients with more severe forms of chronic liver disease and higher MELD-XI scores. While the study adjusted the differences in bleeding rates for baseline markers of renal and hepatic dysfunction, as well as concomitant medication use, it did not account for the progression of these variables over the course of anticoagulant therapy. Additionally, there is always a possibility of unaccounted confounders present due to non-randomized study design. However, we adjusted for the clinical and demographic variables that we reasoned would most likely confound the relationship.
Finally, in this study, we were unable to assess previous exposure to anticoagulant agents prior to the first encounter with our health system. This could falsely shorten the duration of anticoagulation therapy in our study if patients were exposed to anticoagulants before the first record in our database.
It is important to note that our study was underpowered to detect smaller but potentially clinically meaningful differences in bleeding risk. As such, there is a risk of type II error that should prompt clinicians to interpret these results with caution until larger scale studies are available. However, the upper limit of the 95% confidence interval (1.8) suggests that we are unlikely to see overt all-cause bleeding risk increases on DOAC agents. Coupled with the evidence from other studies, these results further support the safe use of DOAC agents in patients with compensated cirrhosis.
In conclusion, this study did not demonstrate significant differences in all-cause and major bleeding in chronic liver disease patients treated with DOAC agents compared to warfarin. Increased MELD-XI score and history of previous bleed were the only identified risk factors for all-cause bleeding. In patients with chronic liver disease and atrial fibrillation, it is important to assess the risks and benefits of long-term anticoagulation. The prevention of stroke or systemic thromboembolism is important, but just as important is minimizing the risk of bleeding. Clinicians should be mindful of individual patient characteristics when choosing an oral anticoagulant agent, while closely monitoring these patients for signs and symptoms of bleeding. Further studies evaluating individual DOAC agents, as well as larger studies replicating these results, are needed to better understand the optimal anticoagulation strategy in setting of chronic liver disease.
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